An internationally renowned industry leader with more than 30 years of experience in drug discovery, development and commercialization at start-ups and established pharmaceutical companies will host the annual Vera Fay Righthand Seminar in Virology this week at Wayne State University School of Medicine.
Ann Kwong, Ph.D., executive vice president of research for Pardes Biosciences, will present “Discovery and Development of PBI-0451 a Novel Oral Protease Inhibitor for the Potential Treatment of SARS-CoV-2” at 11:30 a.m. April 26.
The annual conference, presented by WSU’s Department of Biochemistry, Microbiology, and Immunology, will be held in room 2268 at Scott Hall. The call can also be viewed via Zoom at https://wayne-edu.zoom.us/j/91937758593?pwd=ZklhajhxVUNyQms1dXN6YkhRNlpjZz09 using meeting ID 919 3775 8593 and passcode 599226.
Dr. Kwong’s talk will detail the discovery and development of a SARS-CoV-2 3CL protease inhibitor currently in clinical trial to treat COVID-19.
The 2020 Gertrude Elion Memorial Prize played a crucial role in the development of Incivek, a hepatitis C virus protease inhibitor, approved in 2011; Pimodivir, a first-in-class influenza A PB2 inhibitor currently in phase 3; Merimipodib, an IMPDH inhibitor; and Agenerase, an approved HIV-1 protease inhibitor.
Dr. Kwong’s specialties include infectious disease discovery, particularly antiviral drug discovery, development, regulatory submission and commercialization, and strategic development of new drugs with particular emphasis on the corresponding implications of clinical and commercial needs. to guide the discovery decision and target product profile. She has led small and large cross-functional pharma teams and successfully attracted investors, including raising $11 million for Trek Therapeutics and $77 million for Dewpoint Therapeutics.
For more information, contact Ladislau Kovari, Ph.D., professor and associate chair of biochemistry, microbiology, and immunology, at [email protected]